Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07020819 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

StatusRecruiting
PhasePhase 3
Started2025-09-12
View on ClinicalTrials.gov ↗

Amendment history

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
2026-05-27
Study Status, Contacts/Locations v4
Trial sites expanded: 9 → 13 locations
2026-02-18
Study Status, Contacts/Locations v3
Study sites4→9
2025-12-08
Not Yet Recruiting→Recruiting Study Identification, Study Status, Contacts/Locations, References v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2026-12→2026-12-31
Completion date2028-06→2028-06-30
Start dateestimated 2025-06→confirmed 2025-09-12
Study sites0→4
2025-06-06
Original filing
Annexon, Inc.
5 trials monitored
See 1 trial at risk
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
Trial Details
NCT Number NCT07020819
Lead Sponsor Annexon, Inc.
Conditions Guillain-Barre Syndrome
Enrollment 30 participants
Start Date 2025-09-12
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-28